Post by Nadica (She/Her) on Aug 28, 2024 1:55:18 GMT
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial - Published Aug 27, 2024
In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% rate of confirmed symptomatic COVID-19 compared to an 11.9% rate for participants receiving placebo, an 84% relative risk reduction (nominal p= 0.000061)
In immunocompromised participants, pemivibart demonstrated a rate of 3% of confirmed symptomatic COVID-19, an encouraging potential signal of protection during the assessed time period
CANOPY data from planned exploratory clinical efficacy analyses during the 180-day period that included XBB* and JN.1* virus lineages
Safety profile of pemivibart consistent with previously reported CANOPY clinical trial data
PEMGARDA (pemivibart) Fact Sheet for Healthcare Providers updated by U.S. Food and Drug Administration (FDA) including exploratory clinical efficacy data
Conference call today at 8:30AM EDT to discuss CANOPY data analyses
investors.invivyd.com/node/9076/pdf
In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% rate of confirmed symptomatic COVID-19 compared to an 11.9% rate for participants receiving placebo, an 84% relative risk reduction (nominal p= 0.000061)
In immunocompromised participants, pemivibart demonstrated a rate of 3% of confirmed symptomatic COVID-19, an encouraging potential signal of protection during the assessed time period
CANOPY data from planned exploratory clinical efficacy analyses during the 180-day period that included XBB* and JN.1* virus lineages
Safety profile of pemivibart consistent with previously reported CANOPY clinical trial data
PEMGARDA (pemivibart) Fact Sheet for Healthcare Providers updated by U.S. Food and Drug Administration (FDA) including exploratory clinical efficacy data
Conference call today at 8:30AM EDT to discuss CANOPY data analyses
investors.invivyd.com/node/9076/pdf